254 related articles for article (PubMed ID: 18388919)
1. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
3. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
Sheng L; Wu CY; Chen XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
6. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis.
Ulrich-Vinther M; Carmody EE; Goater JJ; S balle K; O'Keefe RJ; Schwarz EM
J Bone Joint Surg Am; 2002 Aug; 84(8):1405-12. PubMed ID: 12177271
[TBL] [Abstract][Full Text] [Related]
7. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
Uehara H; Takahashi T; Izumi K
Int J Oncol; 2013 Aug; 43(2):365-74. PubMed ID: 23708710
[TBL] [Abstract][Full Text] [Related]
8. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
9. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
10. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
11. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.
Zinonos I; Luo KW; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ko CH; Yue GG; Lau CB; Ingman W; Ponomarev V; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Int J Oncol; 2014 Aug; 45(2):532-40. PubMed ID: 24865346
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
15. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
16. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
Fili S; Karalaki M; Schaller B
Cancer Lett; 2009 Sep; 283(1):10-9. PubMed ID: 19201081
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
[TBL] [Abstract][Full Text] [Related]
19. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model.
Yang SY; Mayton L; Wu B; Goater JJ; Schwarz EM; Wooley PH
Arthritis Rheum; 2002 Sep; 46(9):2514-23. PubMed ID: 12355500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
